Indivior Pharmaceuticals, Inc. (INDV) Stock Price & Analysis
Indivior Pharmaceuticals, Inc. (INDV) rose 2.33% to USD 38.26 as of June 9, 2026 at 23:47 UTC, according to Nexqual real-time market data.
INDV last closed at USD 37.39; the session ranged USD 37.53–38.8 on volume of 1,415,774 shares. Market capitalization is $4.52B, with a 52-week range of USD 13.44–41 (NMS). Source: Nexqual, June 9, 2026 at 23:47 UTC.
Key Statistics (as of June 9, 2026 at 23:47 UTC)
| Price | USD 38.26 |
|---|---|
| Change | ▲ 2.33% (up) |
| Previous Close | USD 37.39 |
| Open | USD 37.95 |
| Day Range | USD 37.53 – 38.8 |
| 52-Week Range | USD 13.44 – 41 |
| Volume | 1,415,774 shares |
| Market Cap | $4.52B |
| Exchange | NMS |
Technical Analysis (INDV)
Nexqual's technical model rates INDV "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 23:47 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.26 (neutral) |
| vs SMA50 | Above (USD 35.12) |
| MACD | 0.35 (positive) |
Analyst Ratings (INDV)
Wall Street analysts rate INDV "None" based on 6 analysts, with a mean price target of USD 51.5 (range USD 48–59), per Nexqual as of June 9, 2026 at 23:47 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 51.5 |
| High Target | USD 59 |
| Low Target | USD 48 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (INDV)
| Next Earnings Date | 2026-04-30 |
|---|---|
| EPS Estimate | USD 0.92 |
| Revenue Estimate | $306.55M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.96 vs est 0.66 ▲ beat |
| 2025-12-31 | USD 0.82 vs est 0.67 ▲ beat |
| 2025-09-30 | USD 0.72 vs est 0.41 ▲ beat |
| 2025-06-30 | USD 0.51 vs est 0.25 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:47 UTC.
Financials & Fundamentals (INDV)
| Total Revenue | $1.29B |
|---|---|
| Revenue Growth (YoY) | +19.20% |
| Gross Margin | +84.96% |
| Operating Margin | +46.06% |
| Profit Margin | +19.53% |
| Current Ratio | 0.86 |
| Total Cash | $175.00M |
| Total Debt | $509.00M |
| Free Cash Flow | $44.25M |
Source: Nexqual, June 9, 2026 at 23:47 UTC.
Financial Health Score (INDV)
Nexqual rates Indivior Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:47 UTC.
| Growth | Mixed — Revenue +4.3% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 85%, operating 46% |
| Balance Sheet | Mixed — $175M cash vs $509M debt |
| Cash Flow | Mixed — FCF $44M, slim 3.6% margin |
| Efficiency | Mixed — No data |
Ownership (INDV)
| Insider Ownership | +4.31% |
|---|---|
| Institutional Ownership | +106.86% |
| Shares Outstanding | 118.20M |
| Float | 110.12M |
| Short % of Float | +13.80% |
Source: Nexqual, June 9, 2026 at 23:47 UTC.
Leadership (INDV)
Indivior Pharmaceuticals, Inc. is led by Joseph J. Ciaffoni (age 54), CEO & Director, per Nexqual as of June 9, 2026 at 23:47 UTC.
| CEO & Director | Joseph J. Ciaffoni (age 54) |
|---|---|
| Chief Financial Officer | Ryan Preblick (age 49) |
| Chief Scientific Officer | Christian Heidbreder (age 62) |
| Vice President of Investor Relations | Jason Thompson |
| Executive Vice President of Corporate Affairs | Vanessa Procter |
Major Backers & Investors (INDV)
Notable institutional backers of Indivior Pharmaceuticals, Inc. include Oaktree Capital Management LP, Two Seas Capital Lp, Millennium Management, according to Nexqual as of June 9, 2026 at 23:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Oaktree Capital Management LP | 5.73% |
| Two Seas Capital Lp | 3.89% |
| Millennium Management | 3.77% |
| Fuller & Thaler Asset Management Inc. | 3.72% |
| Madison Avenue Partners, LP | 3.54% |
| Citadel | 2.93% |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Growth Fund | 2.74% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.87% |
| Vanguard Group | 19.14% |
| State Street | 4.02% |
Source: Nexqual, June 9, 2026 at 23:47 UTC.
From Indivior Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
- It develops medicines to treat substance use disorders.
- The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.
- It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BTSG | BrightSpring Health Services, I | USD 61 | ▲ 6.27% |
| MLYS | Mineralys Therapeutics, Inc. | USD 24.18 | ▲ 2.07% |
| TVTX | Travere Therapeutics, Inc. | USD 48.57 | ▲ 6.02% |
| APGE | Apogee Therapeutics, Inc. | USD 85 | ▼ 2.21% |
| CELC | Celcuity Inc. | USD 92.59 | ▲ 4.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:47 UTC. This page is informational and not investment advice.